Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus VESICARE.
DETROL vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic
Anticholinergic